Protective effects of mesenchymal stromal cells on adriamycin-induced minimal change nephrotic syndrome in rats and possible mechanisms

Cytotherapy

Volumn 16, Issue 4, 2014, Pages 471-484

  Guo, Junqi ^a   Zou, Yuhua ^a   Wu, Zhixian ^a   Wu, Weizhen ^a   Xu, Zizhong ^a   Hu, Heyi ^a   Huang, Lianghu ^a   Dong, Huiyue ^a   Chen, Jin ^a   Lu, Jun ^a   Fu, Yunfen ^a   Wang, Jin ^a   Ma, Yujie ^a   Chen, Xiaowen ^a   He, Fuqiang ^a   Yang, Shunliang ^a   Liao, Lianming ^a   Chen, Jian ^a   Zheng, Feng ^a   Tan, Jianming ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

Mesenchymal stromal cells; Nephrotic syndrome; P21; Synaptopodin

Indexed keywords

CREATININE; DOXORUBICIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PREDNISONE; PROTEIN P21; SYNAPTOPODIN; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL TRANSPLANTATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; IN VITRO STUDY; KIDNEY CORTEX; KIDNEY FUNCTION; MALE; MESENCHYMAL STROMAL CELL TRANSPLANTATION; MINIMAL CHANGE NEPHROTIC SYNDROME; NEPHROTIC SYNDROME; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; THERAPY EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

RATTUS;

MESENCHYMAL STROMAL CELLS; NEPHROTIC SYNDROME; P21; SYNAPTOPODIN;

ANIMALS; CHEMOKINE CCL2; DOXORUBICIN; GENE EXPRESSION REGULATION; HUMANS; KIDNEY; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICROFILAMENT PROTEINS; NEPHROSIS, LIPOID; PREDNISONE; RATS; RHO GTP-BINDING PROTEINS; RNA, MESSENGER;

EID: 84895784132     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.08.002     Document Type: Article

References (58)

1. Wernerson A., Duner F., Pettersson E., Widholm S.M., Berg U., Ruotsalainen V., et al. Altered ultrastructural distribution of nephrin in minimal change nephrotic syndrome. Nephrol Dial Transplant 2003, 18:70-76.
2. Patrakka J., Lahdenkari A.T., Koskimies O., Holmberg C., Wartiovaara J., Jalanko H. The number of podocyte slit diaphragms is decreased in minimal change nephrotic syndrome. Pediatr Res 2002, 52:349-355.
3. Oh J., Kemper M.J. Minimal change (steroid sensitive) nephrotic syndrome in children: new aspects on pathogenesis and treatment. Minerva Pediatr 2012, 64:197-204.
4. Grimbert P., Audard V., Remy P., Lang P., Sahali D. Recent approaches to the pathogenesis of minimal-change nephrotic syndrome. Nephrol Dial Transplant 2003, 18:245-248.
5. Cunard R., Kelly C.J. T cells and minimal change disease. J Am Soc Nephrol 2002, 13:1409-1411.
6. Audard V., Lang P., Sahali D. [Minimal change nephrotic syndrome: new insights into disease pathogenesis]. Med Sci 2008, 24:853-858.
7. Abrahamson D.R. Structure and development of the glomerular capillary wall and basement membrane. Am J Physiol 1987, 253:F783-F794.
8. Kawachi H., Suzuki K., Miyauchi N., Hashimoto T., Otaki Y., Shimizu F. Slit diaphragm dysfunction in proteinuric states: identification of novel therapeutic targets for nephrotic syndrome. Clin Exp Nephrol 2009, 13:275-280.
9. Tryggvason K., Wartiovaara J. Molecular basis of glomerular permselectivity. Curr Opin Nephrol Hypertens 2001, 10:543-549.
10. Gorriz J.L., Martinez-Castelao A. Proteinuria: detection and role in native renal disease progression. Transplant Rev 2012, 26:3-13.
11. Perysinaki G.S., Moysiadis D.K., Bertsias G., Giannopoulou I., Kyriacou K., Nakopoulou L., et al. Podocyte main slit diaphragm proteins, nephrin and podocin, are affected at early stages of lupus nephritis and correlate with disease histology. Lupus 2011, 20:781-791.
12. Jalanko H., Patrakka J., Tryggvason K., Holmberg C. Genetic kidney diseases disclose the pathogenesis of proteinuria. Ann Med 2001, 33:526-533.
13. Mundel P., Shankland S.J. Podocyte biology and response to injury. J Am Soc Nephrol 2002, 13:3005-3015.
14. Tryggvason K. Unraveling the mechanisms of glomerular ultrafiltration: nephrin, a key component of the slit diaphragm. J Am Soc Nephrol 1999, 10:2440-2445.
15. Fukudome K., Fujimoto S., Sato Y., Kitamura K. Comparison of the effects of intravenous methylprednisolone pulse versus oral prednisolone therapies on the first attack of minimal-change nephrotic syndrome in adults. Nephrology 2012, 17:263-268.
16. Fujinaga S., Hirano D., Murakami H., Ohtomo Y., Shimizu T., Kaneko K. Nephrotoxicity of once-daily cyclosporine A in minimal change nephrotic syndrome. Pediatr Nephrol 2012, 27:671-674.
17. Park S.J., Shin J.I. Complications of nephrotic syndrome. Korean J Pediatr 2011, 54:322-328.
18. Scolding N. Stem-cell therapy: hope and hype. Lancet 2005, 365:2073-2075.
19. Imai N., Kaur T., Rosenberg M.E., Gupta S. Cellular therapy of kidney diseases. Semin Dial 2009, 22:629-635.
20. Morigi M., Imberti B., Zoja C., Corna D., Tomasoni S., Abbate M., et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol 2004, 15:1794-1804.
21. Bruno S., Grange C., Deregibus M.C., Calogero R.A., Saviozzi S., Collino F., et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 2009, 20:1053-1067.
22. Choi S.J., Kim J.K., Hwang S.D. Mesenchymal stem cell therapy for chronic renal failure. Exp Opin Biol Ther 2010, 10:1217-1226.
23. van Koppen A., Joles J.A., van Balkom B.W., Lim S.K., de Kleijn D., Giles R.H., et al. Human embryonic mesenchymal stem cell-derived conditioned medium rescues kidney function in rats with established chronic kidney disease. PLoS One 2012, 7:e38746.
24. English K., Barry F.P., Mahon B.P. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett 2008, 115:50-58.
25. Kunter U., Rong S., Boor P., Eitner F., Muller-Newen G., Djuric Z., et al. Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes. J Am Soc Nephrol 2007, 18:1754-1764.
26. Kronsteiner B., Peterbauer-Scherb A., Grillari-Voglauer R., Redl H., Gabriel C., van Griensven M., et al. Human mesenchymal stem cells and renal tubular epithelial cells differentially influence monocyte-derived dendritic cell differentiation and maturation. Cell Immunol 2011, 267:30-38.
27. Hauger O., Frost E.E., van Heeswijk R., Deminiere C., Xue R., Delmas Y., et al. MR evaluation of the glomerular homing of magnetically labeled mesenchymal stem cells in a rat model of nephropathy. Radiology 2006, 238:200-210.
28. Togel F., Hu Z., Weiss K., Isaac J., Lange C., Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005, 289:F31-F42.
29. Humphreys B.D., Valerius M.T., Kobayashi A., Mugford J.W., Soeung S., Duffield J.S., et al. Intrinsic epithelial cells repair the kidney after injury. Cell Stem Cell 2008, 2:284-291.
30. O'Donnell M.P., Michels L., Kasiske B., Raij L., Keane W.F. Adriamycin-induced chronic proteinuria: a structural and functional study. J Lab Clin Med 1985, 106:62-67.
31. Zhuo W., Liao L., Xu T., Wu W., Yang S., Tan J. Mesenchymal stem cells ameliorate ischemia-reperfusion-induced renal dysfunction by improving the antioxidant/oxidant balance in the ischemic kidney. Urol Int 2011, 86:191-196.
32. Krtil J., Platenik J., Kazderova M., Tesar V., Zima T. Culture methods of glomerular podocytes. Kidney Blood Press Res 2007, 30:162-174.
33. Bertani T., Poggi A., Pozzoni R., Delaini F., Sacchi G., Thoua Y., et al. Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. Lab Invest 1982, 46:16-23.
34. Mundel P., Heid H.W., Mundel T.M., Kruger M., Reiser J., Kriz W. Synaptopodin: an actin-associated protein in telencephalic dendrites and renal podocytes. J Cell Biol 1997, 139:193-204.
35. Yang W., Wang J., Shi L., Yu L., Qian Y., Liu Y., et al. Podocyte injury and overexpression of vascular endothelial growth factor and transforming growth factor-beta 1 in adriamycin-induced nephropathy in rats. Cytokine 2012, 59:370-376.
36. Ho J.H., Tseng T.C., Ma W.H., Ong W.K., Chen Y.F., Chen M.H., et al. Multiple intravenous transplantations of mesenchymal stem cells effectively restore long-term blood glucose homeostasis by hepatic engraftment and beta-cell differentiation in streptozocin-induced diabetic mice. Cell Transplant 2012, 21:997-1009.
37. Nakajo A., Khoshnoodi J., Takenaka H., Hagiwara E., Watanabe T., Kawakami H., et al. Mizoribine corrects defective nephrin biogenesis by restoring intracellular energy balance. J Am Soc Nephrol 2007, 18:2554-2564.
38. Shibata S., Nagase M., Fujita T. Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J Am Soc Nephrol 2006, 17:754-764.
39. Villanueva S., Carreno J.E., Salazar L., Vergara C., Strodthoff R., Fajre F., et al. Human mesenchymal stem cells derived from adipose tissue reduce functional and tissue damage in a rat model of chronic renal failure. Clin Sci 2013, 125:199-210.
40. Li W., Jiang H., Feng J.M. Isogenic mesenchymal stem cells transplantation improves a rat model of chronic aristolochic acid nephropathy via upregulation of hepatic growth factor and downregulation of transforming growth factor beta1. Mol Cell Biochem 2012, 368:137-145.
41. Wang S., Li Y., Zhao J., Zhang J., Huang Y. Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model. Biol Blood Marrow Transplant 2013, 19:538-546.
42. Magnasco A., Corselli M., Bertelli R., Ibatici A., Peresi M., Gaggero G., et al. Mesenchymal stem cells protective effect in adriamycin model of nephropathy. Cell Transplant 2008, 17:1157-1167.
43. Togel F., Yang Y., Zhang P., Hu Z., Westenfelder C. Bioluminescence imaging to monitor the in vivo distribution of administered mesenchymal stem cells in acute kidney injury. Am J Physiol Renal Physiol 2008, 295:F315-F321.
44. Ghiggeri G.M., Bertelli R., Ginevri F., Oleggini R., Altieri P., Trivelli A., et al. Multiple mechanisms for doxorubicin cytotoxicity on glomerular epithelial cells 'in vitro'. Eur J Pharmacol 1992, 228:77-83.
45. Ramasamy R., Lam E.W., Soeiro I., Tisato V., Bonnet D., Dazzi F. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia 2007, 21:304-310.
46. Ramasamy R., Fazekasova H., Lam E.W., Soeiro I., Lombardi G., Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 2007, 83:71-76.
47. Pavenstadt H., Kriz W., Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003, 83:253-307.
48. Kriz W. Podocyte is the major culprit accounting for the progression of chronic renal disease. Microsc Res Tech 2002, 57:189-195.
49. Bruno S., Bussolati B. Therapeutic effects of mesenchymal stem cells on renal ischemia-reperfusion injury: a matter of genetic transfer?. Stem Cell Res Ther 2013, 4:55.
50. Fang Y., Tian X., Bai S., Fan J., Hou W., Tong H., et al. Autologous transplantation of adipose-derived mesenchymal stem cells ameliorates streptozotocin-induced diabetic nephropathy in rats by inhibiting oxidative stress, pro-inflammatory cytokines and the p38 MAPK signaling pathway. Int J Mol Med 2012, 30:85-92.
51. Harper J.W., Elledge S.J., Keyomarsi K., Dynlacht B., Tsai L.H., Zhang P., et al. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 1995, 6:387-400.
52. Kfouri F., de Castro I., Testagrossa L., Delle H., da Silva A.M., Bastos A.P., et al. Role of p21 and oxidative stress on renal tubular resistance after acute ischaemic injury. Nephrol Dial Transplant 2010, 25:1795-1803.
53. Price P.M., Safirstein R.L., Megyesi J. The cell cycle and acute kidney injury. Kidney Int 2009, 76:604-613.
54. Shimizu H., Bolati D., Higashiyama Y., Nishijima F., Shimizu K., Niwa T. Indoxyl sulfate upregulates renal expression of MCP-1 via production of ROS and activation of NF-kappaB, p53, ERK, and JNK in proximal tubular cells. Life Sci 2012, 90:525-530.
55. Liu J., Li K., He Y., Zhang J., Wang H., Yang J., et al. Anticubilin antisense RNA ameliorates adriamycin-induced tubulointerstitial injury in experimental rats. Am J Med Sci 2011, 342:494-502.
56. Svobodova E., Krulova M., Zajicova A., Pokorna K., Prochazkova J., Trosan P., et al. The role of mouse mesenchymal stem cells in differentiation of naive T-cells into anti-inflammatory regulatory T-cell or proinflammatory helper T-cell 17 population. Stem Cells Dev 2012, 21:901-910.
57. Tsuda H., Yamahara K., Ishikane S., Otani K., Nakamura A., Sawai K., et al. Allogenic fetal membrane-derived mesenchymal stem cells contribute to renal repair in experimental glomerulonephritis. Am J Physiol Renal Physiol 2010, 299:F1004-F1013.
58. Ohnishi S., Yanagawa B., Tanaka K., Miyahara Y., Obata H., Kataoka M., et al. Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis. J Mol Cell Cardiol 2007, 42:88-97.